Loading organizations...
§ Venture Capital · Chapel Hill, NC, USA
Biopharmaceutical company developing and commercializing therapeutics for viral diseases, liver diseases, and cancer in Mainland China.
Founded in 2013 by Jinzi Jason Wu, Ascletis is a biopharmaceutical company based in Hangzhou, China, that researches, develops, and commercializes therapeutics for viral diseases, liver conditions, and oncology. The publicly traded enterprise manages a clinical pipeline of over twenty distinct drug candidates and employs a workforce of 208 people across its mainland operations. Backed by early institutional investors including C-Bridge Capital and Goldman Sachs, the firm became the first pre-revenue biotech entity to list its shares on the Hong Kong Stock Exchange. During its 2018 initial public offering, the organization raised approximately $400 million to fund clinical trials and commercialization efforts for approved treatments like Ritonavir, GANOVO, and ASCLEVIR. Founder and chief executive officer Jinzi Jason Wu currently retains a 49.56 percent ownership stake in the business, which is valued at HK$4.51 billion.
Ascletis has raised $222.2M across 4 funding rounds.
Key people at Ascletis.
Ascletis was founded by Jinzi Wu (Founder & President , CEO).
Ascletis has raised $222.2M in total across 4 funding rounds.
Ascletis was founded by Jinzi Wu (Founder & President , CEO).
Ascletis has raised $222.2M in total across 4 funding rounds.
Ascletis's investors include C-Bridge Capital, FOCUS Media Jiangnanchun Foundation, Goldman Sachs, Tasly Pharmaceutical, WTT Investment, Hangzhou National Hi-Tech Industrial Development Zone, Hangzhou Binjiang Investment Holding.
Key people at Ascletis.
Ascletis has raised $222.2M across 4 funding rounds. Most recently, it raised $100.6M Series B in January 2017.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 12, 2021 | 3-V Biosciences | $80.0M Other Equity | — | Altium Capital, HM Capital, Invus, Beth Seidenberg, Matt McAviney, PFM Health Sciences, Rock Springs Capital |
| Aug 5, 2019 | 3-V Biosciences | $7.0M Series E Extension | Ascletis | Kleiner Perkins, NEW Enterprise Associates |
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 3, 2017 | $100.6M Series B | C Bridge Capital | FOCUS Media Jiangnanchun Foundation, Goldman Sachs, Tasly Pharmaceutical, WTT Investment | Announced |
| Dec 2, 2015 | $20M Venture Round | Goldman Sachs | — | Announced |
| Jan 4, 2012 | $1.6M Grant | Hangzhou National HI Tech Industrial Development Zone | — | Announced |
| Apr 6, 2011 | $100M Series A | Hangzhou Binjiang Investment Holding | — | Announced |